{
  "id": "real-world-data-show-84-survival-in-children-treated-with-ryoncil-for-sr-agvhd",
  "title": "Real‑world data show 84% survival in children treated with Ryoncil for SR‑aGvHD",
  "summary": "Mesoblast Limited reported that early real‑world commercial experience with Ryoncil® (remestemcel‑L‑rknd) showed that 84 percent of children completed the full 28‑day treatment and were alive, reinforcing the therapy’s potential benefit in practice settings, the company said. Ryoncil has been commercially available in the U.S. since March 2025 for steroid‑refractory acute graft‑versus‑host disease (SR‑aGvHD) in patients aged 2 […] The post Real‑world data show 84% survival in children treated with Ryoncil for SR‑aGvHD appeared first on Longevity.Technology.",
  "url": "https://longevity.technology/news/real-world-data-show-84-survival-in-children-treated-with-ryoncil-for-sr-agvhd/",
  "source": "Longevity.Technology",
  "author": null,
  "category": "news",
  "publishedAt": "2026-01-29T10:36:28.000Z",
  "fetchedAt": "2026-02-04T10:49:05.820Z",
  "relevanceScore": 0.2,
  "matchedKeywords": [
    "longevity"
  ],
  "relatedProducts": [],
  "type": "web",
  "savedAt": "2026-02-04T10:49:05.892Z"
}